25 March 2022 in Cell Death & Disease
Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality with a dismal prognosis that has changed little over the past few decades. Further understanding of the molecular pathology of PDAC progression is urgently required in order to improve the prognosis of patients with PDAC. Herein, it was observed that trefoil factor 3 (TFF3) expression was elevated in PDAC, and was positively correlated with a worse overall patient survival outcome. Forced expression of TFF3 promoted oncogenic functions of PDAC cells in vitro including cell proliferation, survival, foci formation, cancer stem cell-like behavior and invasion, ex vivo colony growth in 3D-Matrigel, and xenograft growth in vivo. Depletion or pharmacological inhibition of TFF3 inhibited these same processes. RNA-Seq analysis and subsequent mechanistic analyses demonstrated that TFF3 increased the expression of various WNT ligands to mediate WNT pathway activation required for TFF3-stimulated PDAC progression. Combined pharmacological inhibition of TFF3 and WNT signaling significantly attenuated PDAC xenograft growth and potentiated the therapeutic efficacy of gemcitabine in both ex vivo and in vivo models. Hence, a mechanistic basis for combined inhibition of pathways enhancing PDAC progression is provided and suggests that inhibition of TFF3 may assist to ameliorate outcomes in PDAC.
12 April 2023 in Leukemia
18 February 2025 in Endocrinology, Diabetes & Metabolism
Background: Polycystic ovary syndrome (PCOS) is one of the commonest gyneco‐endocrine disorders amongst women of reproductive age. Whether PCOS and cardiometabolic traits in PCOS patients are associated with shortened telomere length (TL) or relative leukocyte telomere length (rLTL) remains unclear.Methods: 214 women with PCOS and 214 age‐matched women were recruited. rLTL was measured with an updated quantitative real‐time PCR protocol and reported as ΔΔCt between telomere and a single‐copy gene encoding β‐globin relative to a normalisation control. A two‐way Mendelian randomization analysis using the UK Biobank Resource was performed to assess the causal relationship between rLTL and PCOS.Results: Women with PCOS had significantly shortened rLTL (PCOS: 0.5 ± 0.7; control: 0.8 ± 0.6; p < 0.001). Longer rLTL was associated with a lower risk of PCOS after adjusting for age, history of smoking and other cardiometabolic traits (OR: 0.503; 95% CI: 0.342–0.730; p < 0.001). Longer rLTL was associated with reduced risk of dyslidpidemia (OR: 0.563; 95% CI: 0.450–0.968; p = 0.042) in PCOS patients. PCOS subjects with rLTL shorter than mean of the rLTL of control subjects had an elevated risk of dysglycemia (OR: 2.09; 95% CI: 1.04–4.29; p = 0.040). No causal relationships were found between rLTL and PCOS in the Mendelian randomization study.Conclusions: Women with PCOS have significantly reduced rLTL and shorter LTL may be associated with cardiometabolic risk factors in PCOS subjects. There are no causal relationship between genetically determined PCOS and TL or vice versa.
3 February 2023 in Research Square
Therapeutic resistance is a major challenge in multiple myeloma treatment. Understanding the underlying mechanisms is required to develop effective strategies against drug resistance and improve the prognosis of myeloma patients. Here, we identify osteocytes, the major cellular component of bone tissue, as key regulators of myeloma therapeutic resistance. Osteocyte-derived exosomes can be efficiently taken up by myeloma cells and exert a protective effect against chemotherapy-induced apoptosis. Mechanistic studies further reveal that osteocyte-derived exosomal miR-483-3p and miR-513a-5p promote cancer stem cell-like features in myeloma cells by regulating HIF-1α stabilization, thus conferring myeloma cells resistance to chemotherapy. Strikingly, combination treatment of miR-483-3p and miR-513a-5p inhibitors significantly reduces tumor burden and potentiates the therapeutic efficacy of bortezomib in the myeloma mouse model. Our findings, therefore, demonstrate the functional impact of osteocytes on myeloma therapeutic resistance, and suggest that osteocyte-derived exosomal miRNAs may serve as potential therapeutic targets for overcoming drug resistance in multiple myeloma.
23 September 2019 in bioRxiv
Age-related macular degeneration (AMD) is a leading cause of visual impairment in ageing populations and has no radical treatment or prevention. Although genome-wide association studies (GWAS) have identified many susceptibility loci for AMD, the underlying causal genes remain elusive. Here, we prioritized nine putative causal genes by integrating expression quantitative trait locus (eQTL) data from blood ( n = 2,765) with AMD GWAS data (16,144 cases vs. 17,832 controls) and replicated six of them using retina eQTL data ( n = 523). Of the six genes, altering expression of cnn2 , sarm1 and bloc1s1 led to ocular phenotype, impaired vision and retinal pigment epithelium (RPE) loss in zebrafish. Essential photoreceptor and RPE genes were downregulated in cnn2 - and sarm1 -knockdown zebrafishes. Through integration of GWAS and eQTL data followed by functional validation, our study reveals potential roles of CNN2 , SARM1 and BLOC1S1 in AMD pathogenesis and demonstrates an efficient platform to prioritise causal genes for human complex diseases.